Source: EQS Group AG
DGAP-News: RHÃN-KLINIKUM AG Publishes Provisional Financial Figures for Financial Year 2013
DGAP-News: RHÃN-KLINIKUM AG / Key word(s): Preliminary
Results/Preliminary Results
RHÃN-KLINIKUM AG Publishes Provisional Financial Figures for Financial
Year 2013
13.03.2014 / 07:00
---------------------------------------------------------------------
Number of treated patients rises by 4 percent to approx. 2.65 million
Financial figures for 2013 significantly affected by special influences
Revenues rise by approx. 5 percent to EURO 3.01 billion
EBITDA falls by just under 6 percent to EURO 275 million
Net consolidated profit falls by just under 3 percent to EURO 90 million
Outlook for 2015 confirmed with an EBITDA margin of about 14 percent
The transaction sale of a total of 40 hospitals to Fresenius / Helios which
was commenced during the last financial year and is now largely completed
did not affect the number of patients treated by RHÃN-KLINIKUM AG. Overall
over 2.65 million people were treated in the 54 hospitals which still
belonged to the corporate group in 2013; that is roughly 4 percent more
than during the previous year. Consequently the company's revenue also grew
by approx. 5 percent to approx. EURO 3.01 billion and thus crossed the 3
billion mark for the first time.
However, particularly at the end of the year the transaction required
considerable management resources both at the group headquarters and also
in the individual hospitals. Earnings before interest, taxes, depreciation
and amortisation (EBITDA) thus fell by approx. 6 percent to EURO
275 million despite the increased revenues. Numerous special influences,
such as costs for the necessary staff modifications in the group
administration, considerable consultation expenses in connection with the
sale transaction and other structural one-time effects - totalling between
EURO 30 million and EURO 40 million at EBITDA level - came to bear here.
Against this background the net consolidated profit also decreased slightly
by just under 3 percent to EURO 90 million.
"The achieved earnings are generally satisfactory in consideration of the
challenging framework conditions of handling the sale transaction," Dr. Dr.
Martin Siebert, CEO of RHÃN KLINIKUM AG, explained. In 2013 outstanding
work for the overall benefit of patients was again carried out due to the
dedication of employees despite the uncertainty and extra load associated
with the transaction. "We are now reaping the reward of our work following
the successful sale. We let the shareholders have an appropriate share in
the sales proceeds and also have a more than solid financial basis for the
challenges of the future. With the new corporate structure we will place an
emphasis on increasing efficiency and profitability without cutting back on
the quality of treatment," Jens-Peter Neumann, CFO of RHÃN-KLINIKUM AG,
said.
Outlook
RHÃN-KLINIKUM AG will refrain from giving a target for revenues and
earnings for the current financial year 2014. The prime reasons for this
are the unfinished structural changes in the company and the special
effects which are caused by the sale and included in the balance sheet and
which still have to be dealt with.
The company expects revenues of EURO 1.06 billion to EURO 1.12 billion and
earnings before interest, tax, depreciation and amortisation (EBITDA) of
between EURO 145 million and EURO
155 million for 2015, the first full financial year with the new corporate
structure. Our outlook is subject to any regulatory changes which may
affect reimbursement rates in the coming year.
"A new era has now begun for RHÃN-KLINIKUM AG. With ten hospitals in five
locations and approx. 15,000 employees we shall now concentrate on
expanding our expertise in medical science and remain one of the largest
hospital operators in Germany. With this focussed direction and streamlined
portfolio we can now concentrate all our strength again on offering our
patients first-class yet affordable medical services. This will also have a
positive effect on the level of earnings in the foreseeable future," Dr.
Dr. Martin Siebert concluded.
Summary of Key Ratios*
2013 2012 Change in %
Patients treated 2,654,249 2,555,822 +3.9 %
Revenues in million EURO 3,014 2,865 +5.2 %
EBITDA in million EURO 275 292 -5.7 %
Net consolidated profit 90 92 -2.6 %
in million EURO
* Provisional, uncertified financial figures with possible rounding-off
differences
**************************************************************************
RHÃN-KLINIKUM AG is one of the largest healthcare providers in Germany.
With ten hospitals in five locations and a total of 5,300 beds the company
intends to expand its expertise in medical science. The hospitals in
Boizenburg, Cuxhaven and Waltershausen-Friedrichroda also currently belong
to the corporate group. A total of approx. 15,000 employees work for
RHÃN-KLINIKUM AG.
Further information is available at: www.rhoen-klinikum-ag.com.
Your Contact Persons:
RHÃN-KLINIKUM AG
Achim Struchholz
Group Division Head of Corporate Communication
Schlossplatz 1
97616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1327
Facsimile: + 49 - 9771 65-1820
E-Mail: kommunikation@rhoen-klinikum-ag.com
Dr. Kai G. Klinger
Head of Investor Relations
Schlossplatz 1
97616 Bad Neustadt / Saale
Telephone: + 49 - 9771 65-1318
Facsimile: + 49 - 9771 99-1736
E-Mail: kai.klinger@rhoen-klinikum-ag.com
End of Corporate News
---------------------------------------------------------------------
13.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: RHÃN-KLINIKUM AG
Schlossplatz 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), München;
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
257271 13.03.2014